This company is engaged in the development of FDA-approved therapies for rare diseases, specifically focusing on diabetes mellitus and type 1 diabetes mellitus.
0
Orphan Designations
9
FDA Approvals
Latest: ERAXIS (2006)
0
Active Trials
200 recruiting
2
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Roerig is a company with 0 orphan drug designations across 2 rare diseases, including 9 FDA-approved therapies. 5 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| diabetes mellitus | GLUCOTROL XL | Des.TrialAppr. |
| type 1 diabetes mellitus | GLUCOTROL XL | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
5
affecting portfolio
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
5
affecting portfolio